frontiers in Physiology

# Waning immunity is associated with periodic large outbreaks of mumps: a mathematical modelling study of Scottish data

DALILA HAMAMI[1*], Ross Cameron[2], Kevin Pollock[2], Carron Shankland[3]

[1]University of Oran1 Ahmed BenBella, Algeria, Algeria, [2]Health Protection Scotland, United Kingdom, [3]Computing science and Mathematics, University of Stirling, United Kingdom

*Submitted to Journal:*
Frontiers in Physiology

*Specialty Section:*
Computational Physiology and Medicine

*ISSN:*
1664-042X

*Article type:*
Original Research Article

*Received on:*
31 Jan 2017

*Accepted on:*
03 Apr 2017

*Provisional PDF published on:*
03 Apr 2017

*Frontiers website link:*
www.frontiersin.org

*Citation:*
Hamami D, Cameron R, Pollock K and Shankland C(2017) Waning immunity is associated with periodic large outbreaks of mumps: a mathematical modelling study of Scottish data. *Front. Physiol.* 8:233. doi:10.3389/fphys.2017.00233

# Waning immunity is associated with periodic large outbreaks of mumps: a mathematical modelling study of Scottish data

**D.Hamami[1*], R.Cameron[2], K.G.Pollock[2], C.Shankland[3]**

[1]University of Oran1 Ahmed BenBella, Algeria

[2]Health Protection Scotland, Glasgow, UK

[3]University of Stirling, UK

*** Correspondence:**
dalila.hamami@univ-mosta.dz; dhamami@gmail.com

**Keywords: Mumps, vaccination, waning immunity, mathematical and computational modelling and simulation, Bio-PEPA**

## Abstract

Vaccination programs for childhood diseases, such as measles, mumps and rubella have greatly contributed to decreasing the incidence and impact of those diseases. Nonetheless, despite long vaccination programmes across the world, mumps has not yet been eradicated in those countries: indeed, large outbreaks continue. For example, in Scotland large outbreaks occurred in 2004, 2005 and 2015, despite introducing the MMR (Measles- Mumps- Rubella) vaccine more than twenty years ago. There are indications that this vaccine-preventable disease is re-emerging in highly vaccinated populations. Here we investigate whether the resurgence of mumps is due to waning immunity, and further, could a booster dose be the solution to eradicate mumps or would it just extend the period of waning immunity? Using mathematical modelling we enhance a seasonally-structured disease model with four scenarios: no vaccination, vaccinated individuals protected for life, vaccinated individuals at risk of waning immunity, and introduction of measures to increase immunity (a third dose, or a better vaccine). The model is parameterised from observed clinical data in Scotland 2004-2015 and the literature. The results of the four scenarios are compared with observed clinical data 2004-2016. While the force of infection is relatively sensitive to the duration of immunity and the number of boosters undertaken, we conclude that periodic large outbreaks of mumps will be sustained for all except the second scenario. This suggests that the current protocol of two vaccinations is optimal in the sense that while there are periodic large outbreaks, the severity of cases in vaccinated individuals is less than in unvaccinated individuals, and the size of the outbreaks does not decrease sufficiently with a third booster to make economic sense. This recommendation relies on continuous efforts to maintain high levels of vaccination uptake.



## 1 Introduction

To prevent, control and eradicate childhood diseases, vaccination programs have been adopted throughout the world. For example the trivalent measles-mumps-rubella vaccine (MMR) [1, 2, 3] has been highly successful for both measles and rubella reduction in many countries. Despite near eradication of both measles and rubella [4,5,6], elimination of mumps has not been achieved and could be considered to be re-emerging, despite initial early success in reducing mumps cases. In the

last decade, many countries such as Belgium [7], Korea [8], the Netherlands [9] and the US [10] have reported a dramatic increase in the incidence of mumps. In Scotland, 2004/2005 saw a sudden high resurgence in mumps with approximately 4500 cases, eight years after the second dose of MMR was included in the vaccination program (which was predicted to substantially reduce mumps outbreaks [11]). One hypothesis is that the resurgence was related to declining vaccine coverage [12, 13], in particular, a widespread scare related to autism which led to some parents refusing to vaccinate their children. This can be easily debunked: the herd immunity threshold is estimated at 75-86% [14] and mumps vaccination levels have stayed above that level (e.g. in Scotland, ranging from 87% to 94% pre-2004). In addition Donaghy et al [14] argues that those infected during the 2004/2005 epidemics are characterised by low uptake of a single dose of MMR (catch-up campaign) and being of school age at time when the mumps virus had greatly reduced circulation in that group, delaying infection. The study undertaken by DeStefano et al [15] analysing the number of antigens in both children with and without autism, shows that there is no association between receiving vaccine and developing autism.

A second hypothesis is to link vaccination status and age, e.g. proposing that outbreaks continue in the older population but die out in the increasingly vaccinated population. However, while age structure has shown to be informative in many models of traditionally childhood diseases [16, 17, 18, 19], current studies suggest that age is not the key determinant in mumps. Snijders et al. [20] do not find any significant interaction between these two features. In addition, several studies of different outbreaks occurring at different times and locations in the US and Canada [21] indicate that there is no evidence that age is the main factor leading to mumps spread. For instance, the outbreaks occurring in New York (Sulivan, Brooklyn, Rockland county and Orange county), New Jersey and Canada show variable average of infected age groups (Sullivan: 12 years, Brooklyn: 14 years, Rockland county: 12 years, Orange county: 18 years, New Jersey: 19.5 years and Canada: 27.5). However, it was confirmed that all cited cases were related to religious events or camping in Sullivan, with the majority fully vaccinated. It was also reported that the series of outbreaks were due to one fully vaccinated child aged 11 years who had been infected during his travel to UK. Snidjer et al. [20] analysed a group of infected whose ages ranged in 3 to 13 years. The authors find out that no significant difference between the attack rate of the group aged 10-13 years and 3-5 years. Considering Scotland specifically, Donaghy et al. [14] argued that the shift of ages observed in the epidemic in Scotland suggests that the propagation of mumps is becoming more widespread and diverse as the targeted population becomes more dynamic and mobile.

Having rejected the first two hypotheses, the arguments used lead to the third and more plausible hypothesis: MMR vaccine efficacy against mumps reduces over time [13]. In 2015 67% of those infected in Scotland were fully vaccinated individuals (1 and 2 doses confounded). Moreover, most primary cases occurred in adolescent and young adults, in contrast to the pre-vaccine era where outbreaks were among children of primary school age. Similar patterns can be found for Belgium in 2012 [7] and in the US in 2006 [10]. Serological studies [8, 22] show that susceptibility level increases (immunity wanes) as time from vaccination increases; however, the antibody threshold defining the protective level is not well specified for mumps [23]. Even using two doses of the MMR vaccine, existing analyses [8, 24] stress that some of the population will remain at risk of disease unless additional control strategies are adopted.

We investigate the hypothesis of waning immunity using mathematically-based computational modelling. The basic model is a seasonal compartmental SEIR model [25, 26, 27], to which vaccination and immunity is added. We first show that the model produces comparable results to observed mumps data in Scotland [28], matching endemic levels of mumps with occasional larger

epidemics, as in 2005 and 2015. Having established the accuracy of the model with historical data, we use it predictively to better understand the relationship between immunity and transmission, to illuminate long-term patterns of resurgent outbreaks, and to determine whether these can be controlled by extending immunity duration (e.g. by using another booster). While modelling has been previously used to investigate mumps and vaccination [7, 27, 29], the novelty of our approach lies in consideration of waning immunity and associated optimal control strategies. Our model shows clearly that waning immunity is a driver for a long period of oscillating outbreaks. Moreover, by working with epidemiologists to use mathematics to understand the observed clinical data, we illustrate the power of mathematics to inform public health policy through multi-disciplinary collaboration.

## 2 Mumps epidemiology in Scotland

During the period 1988-2015, Health Protection Scotland (HPS), the national surveillance centre for Scotland, reported 10943 mumps cases. 10486 of these cases were between 2004 and 2015. Vaccination was introduced in 1988, with a second dose introduced in 1996. Fig. 1 shows the epidemic curve of mumps, and the vaccination uptake curves for both vaccines (MMR1 and MMR2). Observe the initial success of the vaccine (1988-2003) contrasted with a long potential cycle from 2004-2015, possible with sub-cycles (2005-2009, 2009-2012, 2012-2015). The 2004/2005 outbreak was related only partly to the decrease in vaccination coverage shown in Fig. 1 [14]. The majority of cases (94%) were born before 1990 (aged 15+ years), with only a few of them receiving only one dose of MMR (around 1%) or none at all. Similarly for the outbreaks in 2009 and 2012. In 2015 the highest incidence of mumps (63%) was related to the group born 1991-2000 (aged 15-24 years). Cameron and Smith-Palmer [24] argue that the 2015 outbreak was the first where the majority of cases were fully vaccinated. Transmission is a complex feature to model as it can be influenced by many factors (vaccination history, current immunity status, age, opportunity for social mixing, geography, and so on). Moreover, some of these factors are confounded (e.g. age and vaccination history). We propose in this model that vaccination history is used as a proxy for these combined effects. Therefore, the main question arising is: why are vaccinated individuals being infected? Here we focus on the long curve (2005-2015) relating to the long inter-epidemic period. We explore these features within the model presented in Section 3, using the Bio-PEPA plugin tool [30] and deterministic simulation to provide time series prediction of the number of infected individuals. The model is parameterised and validated on data up to 2015, and then to further validate its predictive performance it is shown to match 2016 data provided by HPS. The advantages for using the Bio-PEPA formalism (a mathematically-defined computational modelling approach called process algebra) have been fully argued in many works [30, 31, 32]. Here, the advantages are: formal structuring of interactions between components, a compositional approach to building the epidemiological model, and a range of analysis techniques to support the modeller in understanding the system. The underlying semantics of Bio-PEPA is a continuous time Markov chain.

## 3 Methods

### 3.1 Model structure, epidemiological assumptions and parameter estimates

We consider a compartmental structure for a model of mumps formulated as an extended SEIR [11] model including seasonality and waning immunity: natively susceptible (S1), vaccinated individuals with MMR1 only (V1), vaccinated individuals with both MMR1 and MMR2 (V2), modified susceptible who are vaccinated individuals who have become susceptible (S2), exposed individuals

(E), infected individuals (I) and recovered individuals who are regarded as immune for life (R) [11, 33]. Fig. 2 shows how these compartments interact.

Our goal is to provide as simple a model as is necessary to demonstrate the impact of waning immunity, therefore we have ignored features which others have chosen to include. For example, the models of Glass and Grenfell [34] and Barbarossa and Röst [35] include immunity levels and immune-boosting through vaccination and interactions with infected. Since we have no data on antibody levels as individuals interact we choose not to include this, choosing the simpler scenario which can be parameterised through observed data. Neither do we include age-structure, as mumps has ceased to be a mainly childhood disease. As shown in several works [14, 36, 37, 38], the range of those infected with mumps has become more diverse due to a more mobile susceptible population. Therefore, rather than stratifying the population by age, we assume a more homogenously-mixed population, with routine vaccination, and transmission based on seasonality and immunity status.

This model is general and could be parameterised for any seasonal disease with up to two vaccinations. We use data from Health Protection Scotland (HPS) from 2004-2016 [28] and some parameters from the literature [11, 39]. These are detailed in Table 1, with some explanatory text.

- Demographic estimation

Birth and death rate estimated from Scottish demographic data [28].

- Immigration rate estimation

As the net migration to Scotland is insignificant (typically 15,000 per year), the model has been simplified by having neither mass emigration nor immigration of susceptible individuals. A small constant rate of immigration of infected individuals is required to prevent the disease dying out entirely. This is justified by the knowledge that there is immigration, and there are many populations in the world where mumps is more prevalent and the global population is more mobile, transmitting disease between countries. A small rate of immigration of infectious individuals is estimated as in Finkenstadt et al [40] and Benkirane et al [31].

- Vaccination rates estimation ($\mu_2$, $\mu_3$)

According to vaccination data [41], our basic assumption is an average of 94% MMR1 vaccination coverage (1988-2016) for children aged 0 to 2 years and 90% MMR2 vaccination coverage (1996-2016) for children aged 3 to 5 years. According to past vaccination history [42, 43], we estimate the susceptible portion of the remaining unvaccinated population at 20%. Within that proportion of susceptible we consider 11% of those to be aged ten years or over according to current demographics. It would be more realistic to consider a varying vaccination rate each year; however, we did not want this to confound the patterns obtained through simply waning immunity. We do investigate scenarios in which these average vaccination rates are varied across the simulation period, to show how this affects the pattern of outbreaks.

- Waning immunity estimation ($\tau$, $\delta$)

Our basic assumption is individuals vaccinated with MMR1 and MMR2 (resp. only MMR1) are temporarily protected and that immunity wanes towards susceptibility at constant rate $\delta$ (resp. $\tau$). Lebaron et al [23] report low antibody levels 4-9 years after MMR1 only, and 7-12 years after MMR2 administration. We also investigate scenarios in which these rates are varied.

- Transmission rate estimation (β1, β2, β3)

In our model, the transmission rate depends on two features: seasonality (High, Low) and type of susceptible (native susceptible, modified susceptible) giving four rates: β1 (High season and native susceptible), β2 (high season and modified susceptible, β3 (low season and native susceptible), β4 (low season and modified susceptible). For seasonality, data report higher number of cases October to May, and fewer between June and September [28]. As most cases occurs in 17-24 year-olds this seasonality is further supported through an assumption that many of that group are likely to be in full-time education, and mixing more in semester-time than in the holiday. As the total number of infected at low season is small we assume β3 = β4. In addition, we assume β2 > β1 (transmission in modified susceptible is higher than in native susceptible). This follows from the model of Scherer and McLean [45], and is supported by the report of Cameron [44] that within 205 confirmed cases related to two health boards, 137 (67%) individuals were fully vaccinated. As transmission rate is based on the basic reproduction number $R_0$ (see Table 1), a range of proposed values were collected from literature [11, 13, 27], where $R_0$ is ranged [4-11]. See section 5 for sensitivity analysis of the particular choices of these rates.

- Incubation rate α and recovery rate γ

Established empirical studies [11, 27] estimate the incubation period between 12-25 days and the infectious period between 7-9 days [27]. For modelling convenience, we assume the same period of infection and incubation [43] for both natively susceptible and modified susceptible.

- Initial conditions

The initial mix of susceptible, vaccinated, exposed, infected and recovered is calculated for 1996 according to the above assumptions about population based on vaccination beginning in 1988. See appendix 1 (model component).

The description of the model and parameters above can be summarised by seven ordinary differential equations:

$$\frac{dS1}{dt} = \mu 1 * N - \frac{\beta(t) S1 I}{N} - \mu S1$$

$$\frac{dV1}{dt} = \mu 2 * N - \tau V1 - \mu V1$$

$$\frac{dV2}{dt} = \mu 3 * N - \delta V2 - \mu V2$$

$$\frac{dS2}{dt} = \delta V2 + \tau V1 - \frac{\acute{\beta}(t) S2 I}{N} - \mu S2$$

$$\frac{dE}{dt} = \frac{\beta(t) S1 I}{N} + \frac{\acute{\beta}(t) S2 I}{N} - \alpha E - \mu E$$

$$\frac{dI}{dt} = \alpha E - \gamma I - \mu I + IMM$$

$$\frac{dR}{dt} = \gamma I - \mu R$$

Where: $$\beta(t)\{resp.\ \acute{\beta}(t)\} = \begin{cases} \beta 1\ \{resp.\ \beta 2(t)\}\ if\ Time\ \in [October - May] \\ \beta 3\ if\ Time\ \in [June - September] \end{cases}$$

This model is coded in Bio-PEPA (see Appendix 1). Analysis of the model is performed through deterministic simulation. Stochastic simulation was used to guide model development but does not provide additional information when identifying long term trends.

### 3.2 Model scenarios

To capture the impact of vaccination efficacy and the effect of waning immunity on the population of Scotland for future projection of epidemics, the history of mumps epidemics (from pre-vaccine to post-vaccine era) are reproduced where four strategies are considered:

- *Scenario one.* No vaccination. This is equivalent to the pre-vaccine era and useful for model validation where the whole population is considered susceptible.

- *Scenario two.* Immunity does not wane: $\tau$ and $\delta$ are zero. This case reflects the introduction of a vaccination protocol to case one, where immunity is assumed to be for life. This is consistent with the period immediately following the introduction of vaccination.

- *Scenario three.* Immunity wanes in vaccinated individuals according to the assumptions above. This scenario reflects modern reality, where mumps is resurgent. Our model is extended to two separate but correlated models: the first model expresses unvaccinated individuals and the second model expresses vaccinated individuals for whom immunity wanes. Scenario three is an extension to case two by introducing the terminology of waning immunity.

- *Scenario four.* An additional medical intervention increases immunity duration. We explore immunity duration across a range (10 to 80 years). This case is a particular variation of case three, where the immunity duration is specified in the defined range. This scenario is to predictively investigate possible future interventions.

## 4 Results

According to observed mumps data in Scotland in Fig. 1, and in conjunction with observed mumps data in England and Wales in Fig. 9 (a and b) (see Appendix 3), three different periods of an epidemiological shift in incidence are observed: pre-vaccine, successful post-vaccine and waning immunity period. Fig. 3 depicts time series results for infected cases under scenarios 1-3. Overall, it is clear that mumps occurs every year, regardless of vaccination or waning immunity; however, those factors control the amplitude of the epidemic and the frequency of the highest peaks driving a long term damping oscillation of large outbreaks. After 100 years the difference between the high and low of the cycle is around 25 cases.

*Scenario One (no vaccination = pre-vaccine era)*

We begin by checking model performance without vaccine. Fig. 3 (a) shows an inter-epidemic period of three years within an oscillatory pattern of mumps cases. This matches parameter values of incubation period of 13 days, infectious period of seven days and a mean age of infection of five years (all within the ranges of Table 1). This is supported by the incidence of mumps in England and Wales [27] and observations in the literature reporting cycles of 2-5 years [29, 46].

We point out that predicted cycles do not damp out during 100 years of simulations. By varying seasonality parameter of the model, including removing seasonality altogether, we observed that after a long period the model reaches an endemic state. To further reinforce the suitability of the model we considered $R_0$ ranging from [7 - 14]. Fig. 4 (see Appendix 3) shows that increasing $R_0$ leads to decreasing the inter-epidemic period from 5 years to 3 years.

*Scenario Two (up to two vaccinations and immunity is permanent = immediate post-vaccine era)*

Turning to the successful post-vaccine era (and assuming life-long immunity), Fig. 3 (b) and (d) show a massive decrease of mumps infections consistent with observed data 1988-2003, where waning immunity was not yet an important factor and the number of cases overall dramatically decreased due to the decreased pool of susceptibles, in turn due to vaccination. Again, this helps to confirm that the model successfully models historical data.

*Scenario Three (up to two vaccinations and immunity wanes)*

Fig. 3 (c) (resp. Fig.3 (d)) shows model prediction against observations from Scotland in the post-vaccine era (2004-2016, resp. 1996-2016). Fig. 3 (c) shows pattern of mumps outbreaks from 2004 to 2016 as waning immunity begins to be more relevant. The simulated data (black solid line) displayed in Fig. 3 (c) depicts patterns of mumps dynamics qualitatively similar to observed data (gray solid line). Mumps is notoriously under-reported [47] as, especially for those in whom immunity has waned, the disease is often milder (and infected do not seek medical attention). Our model has no notion of "level" of infection, therefore sub-clinical, mild, and serious infections are all counted and contribute to disease transmission. Observed data is scaled by two to compensate for under-reporting of mumps. This is a conservative estimate, based on higher uptake of vaccine in Scotland than in Germany [47]. This is discussed further in section 6.

Fig. 3 (d) shows that 2005/2015 years were the dominant period reflecting the highest peaks of mumps infection. Some notable gaps are observed (2009, 2010 and 2012); the observed mumps dynamics are inherently stochastic and noisy. Fig. 3 (c,d) depicts that the simulated data for the year 2016 follows the same patterns as observed data, where the number of infected start to decrease. Qualitatively, the simulation results show that even if vaccination is applied, mumps is occurring each year, where the seasonal patterns of our model depict that the infection increases rapidly over the last few months of the year and the high peak is reached early at the start of the year. This is broadly in agreement with observed data.

Vaccination coverage dips in this period, but this is not the main factor leading to the resurgence and sustainability of mumps, nor is seasonality on its own (as above). We investigate the variability of vaccination coverage by ranging its value from [75 - 95], where 75% is the minimum value related to the threshold level and 95% is the maximum value of applied vaccine coverage in Scotland. Fig. 5 (see Appendix 3) shows that increasing vaccine coverage leads to a decrease in the peak of infected[1] (from 1694 to 1413). This is 16%, and still produces a large number of cases. Therefore, increasing the vaccination coverage does not prevent disease occurrence. In addition, we note that all experiments (vaccination coverage ranging from [80 – 95]) settle into a ten year pattern of gently

[1] Average number of infected corresponds to the average of the highest peaks during 100 years of simulations.

damping oscillations (100 years of simulation), where the large oscillations are up to 2045, and thereafter the outbreaks become more and more regular in height.

To further investigate the impact of waning immunity Fig. 6 depicts separately those infected-unvaccinated and those infected-vaccinated against natively susceptible and modified susceptible over 100 years of temporal prediction. As expected, due to increasing levels of vaccinated individuals in the population, the number of natively susceptibles and infected-unvaccinated decreases over time, reaching a steady state of infection of around 200 individuals. Conversely, waning immunity leads to an increase in the number of modified susceptible and infected-vaccinated, settling into a ten year pattern with peaks of between 800 and 1200. Therefore, waning immunity and its effects are the dominant portion of any epidemic.

*Scenario Four (additional booster - up to three vaccinations and immunity wanes)*

Further, we consider scenario 4: the impact of increasing the period of immunity by applying an additional dose of MMR [44]. This could be similarly done by increasing immunity by increasing the efficacy of the vaccination [43]. We investigate increasing immunity duration in steps from 10 to 80 years (broadly, life expectancy). Fig. 7 compares these scenarios and shows that the average of the number of infected individuals at the peak of each outbreak decreases with increasing duration of immunity, as expected.

## 5 Sensitivity analysis

The results above depend on precise parameter values, therefore we used sensitivity analysis to show that the qualitative results of periodic large outbreaks hold across the range. We identify significant parameters reproducing first the observed data, and second leading to the low level endemic state. Table 2 shows the impact on epidemic amplitude and the periodicity of damping cycles of a series of experiments during 100 years of simulation varying model parameter values for: transmission rates ($\beta_1$, $\beta_2$, $\beta_3$), infectious period ($\gamma$), incubation period ($\alpha$), immunity duration ($\tau$, $\delta$) and vaccination rate. The values of the remaining parameters (birth rate, death rate and immigration rate) are fixed.

For all analysis we used ANOVA as implemented in Minitab [48]. The full details of the analysis are in Appendix 2: as expected, only varying transmission rates and immunity duration impact on results. Increasing $R_0$ leads to a decrease in period between large outbreaks and therefore an increase in the number of oscillations (see Fig. 8, Appendix 3). Smaller immunity durations increase the pool of susceptibles faster and therefore lead to larger and earlier epidemics.

## 6 Discussion

Our analysis shows that mumps epidemics will continue, with larger outbreaks of ~1200 every 10 years as shown in Fig 6, eventually settling into an endemic state. This is despite high vaccination coverage against mumps (87- 95%) since 1988 in Scotland [28] (well above the estimated herd immunity threshold of 75-86% [14]).

In this paper, we have presented the results of mathematical modelling using Bio-PEPA, identifying the impact of vaccination and waning immunity in the mumps component of the MMR vaccine. Even though vaccination has been ongoing since 1988, thus largely preventing mumps in children, our results show that waning immunity is the main factor in a repeated pattern of outbreaks. Simulations and analysis undertaken showed that waning immunity over 10 years leads to the highest number of infected and to the longest inter-epidemic period for larger outbreaks.

The first part of this study was to build a seasonal model which reproduces the patterns of the observed data in three scenarios: no vaccination, initial post-vaccine period with immunity for life, and with waning of vaccine-induced immunity as suggested by several sources [7, 8, 9, 10]. Those show that mumps is present in previously vaccinated individuals with the majority of those affected being university students. While based on Scottish data this is not a peculiarly Scottish phenomenon: for example, in the US [1], Korea [8] and the Netherlands [9] adolescent individuals were notified as infected despite high vaccine coverage. In these countries, it was observed that the majority of cases were in young adult (18 to 25 years) who have been fully vaccinated. In the US, where the first dose of MMR was introduced in 1977 and the second dose in 1990, the outbreak occurring in 2006 reached 6584 cases,63% of whom received two doses of vaccine. For this country it was reported that in 1982 the incidence rate was reduced to 97% and the three year cycles observed in the pre-vaccine era disappeared. Moreover, in 2005, one year before the resurgence of the outbreak occurred in 2006, the incidence rate was damped to up to 99% where the vaccine coverage reached 91.5%. In the Netherlands, the large epidemic which occurred in 2004 led to the reintroduction of mumps as a notifiable disease. This followed its removal from the notifiable disease register in 1999 as a consequence of low outbreaks and vaccination coverage of at least one dose of MMR of at least 93% since the introduction of routine vaccine in 1987 . In Korea, the epidemic of 2013-2014 showed that 99% of infected individuals aged from 13 to 18 years have been fully vaccinated. It is worth noting that Korea is not that different from other countries as in the pre-vaccine era the epidemic cycles were identified at 4 to 5 years and the mean age of infection at 4 to 6 years which shifted to teenagers in the recent outbreaks (2007 and 2013) in time when vaccination coverage rose to 90%.

Waning immunity is expressed in our model by including an additional compartment of modified susceptible, which is increased by vaccinated individuals (MMR1 and MMR2) losing their immunity. We find that assuming 5 years of MMR1 vaccine-induced immunity (resp. 10 years of MMR2 vaccine-induced immunity) generates simulation results consistent with more recent mumps post-vaccine data from Scotland (2004-2015). In addition, as our model suggests a ten-year-long gradually damping oscillation, the following trajectory of mumps disease would show a decrease in 2016 and so on, building back up from 2020 to another high peak in the year 2025. The most recent data provided by HPS has confirmed this prediction, where the year 2016 depicts 215 cases compared to 2015 which defines 836 cases. Although our estimates of the amplitude of mumps epidemics are higher than observed data, we conjecture that this can be explained by a low level of reporting. Anecdotally, cases of mumps in vaccinated individuals have much milder symptoms and therefore may be undetected [43, 47, 49, 50]..

By considering different values of immunity duration (scenario 4) we can estimate the time needed to reverse the epidemic trend and eliminate mumps. This models the situation that, for example, a new, more effective, vaccine is introduced, or a third vaccine dose is introduced into the national programme. This is shown in Fig 7. Even extending immunity to 80 years, a reasonable lifespan, mumps outbreaks still occur. Only by further increasing immunity duration to 150 years eliminates mumps outbreaks, assuming no perturbations occur such as a new vaccine or new strain of mumps.

It is worth noting that the basic reproductive number $R_0$ for the pre-vaccine era is estimated at 10.5 which falls in the range [7-14] as cited in literature [11, 39] and for the post-vaccine era $R_0$ is estimated at 6 where in the literature it is quoted at [4-7] [29, 51]. Recall that $R_0$ indicates the number of secondary infections, clearly showing that the number of doses of vaccination and immunity duration has a great impact on decreasing infectious contacts.

Cumulatively, our findings suggest that the more "unprotected" individuals (who were either never vaccinated or lost their immunity), the shorter the period between two high peaks of epidemic outbreak (note the number of cycles in Table 2 for varying values of $R_0$). In addition, in both cases related to scenarios 1 and 3 (No vaccination and waning immunity), an earlier high peak of mumps is expected. This occurs because the pool of susceptibles is increasing faster as those vaccinated lose their immunity and move to the susceptible state (scenario 3), or the pool of susceptibles is decreasing faster when no vaccination is applied and $R_0$ is higher (scenario 1). Clearly, controlling the number of susceptible individuals has a great impact on controlling disease. As argued by Gay [52]: to achieve elimination of an epidemic, low levels of susceptible individuals should be maintained, leading the basic reproductive number ($R_0$) to be less than 1. We do this here by adjusting immunity duration.

These conclusions illustrate an enhanced understanding of mumps disease in response to mass immunization gained through mathematical modelling. Further, our multi-disciplinary team could explore the potential impact of further vaccination on cyclic outbreaks. Our conclusion for public health services is that they should urge vaccine uptake in those eligible since a high degree of protection is offered by the vaccine overall for those under 18. Considering the possible economic cost/benefit of a third vaccine dose, it seems that while there would be an increased period of immunity, the cyclic outbreaks would continue at about 2/3 the current level, therefore this would not offer significant advantages over the present situation. The Joint Committee on Vaccination and Immunization[2] do not consider these large outbreaks of particular concern, since there has been no formal discussion to introduce a 3rd vaccine dose into the national programme.

We suggest further study with this model could include vaccination programmes targeted to those subject to waning immunity or at higher risk due to social mixing in a diverse population (as in higher education). Such a model might also include economic factors to allow the effect of targeted programmes to be more precisely evaluated. Another interesting facet would be to bring more attention to the level of immunity by analysing the vaccine/virus content and detect eventual discrepancy between vaccine strain and mumps outbreak. This might also be linked with a data science approach to analysing serology of confirmed cases. There are further opportunities to use data science to analyse other features, such as geographic distribution. These developments would allow an enhanced version of Fig. 6 showing waves of outbreaks related to waning immunity, evolution of strains of mumps, and locality.

## 7 Conflict of Interest

*The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest*.

## 8 Author Contributions

- The Conception or design of the work: C.Shankland, D.Hamami, K.Pollock
- Data collection: R.Cameron, K.Pollock
- Data analysis and interpretation: C.Shankland, D.Hamami, K.Pollock

[2] UK body advising government health policy on vaccination and immunisation.

- Drafting the article: D.Hamami, C.Shankland
- Critical revision of the article: C.Shankland, K.Pollock, D.Hamami, R.Cameron
- Final approval of the version to be published: C.Shankland, K.Pollock, D.Hamami, R.Cameron

## 9 Reference

[1] Harling, R., White, J. M., Ramsay, M. E., Macsween, K. F., & van den Bosch, C. (2005). The effectiveness of the mumps component of the MMR vaccine: a case control study. *Vaccine*, *23*(31), 4070-4074.

[2] Le Menach, A., Boxall, N., Amirthalingam, G., Maddock, L., Balasegaram, S., & Mindlin, M. (2014). Increased measles–mumps–rubella (MMR) vaccine uptake in the context of a targeted immunisation campaign during a measles outbreak in a vaccine-reluctant community in England. *Vaccine*, *32*(10), 1147-1152.

[3] Cordeiro, E., Ferreira, M., Rodrigues, F., Palminha, P., Vinagre, E., & Pimentel, J. P. (2015). Mumps Outbreak among Highly Vaccinated Teenagers and Children in the Central Region of Portugal, 2012-2013. *Acta medica portuguesa*, *28*(4), 435-441.

[4] Glass, K., & Grenfell, B. T. (2004). Waning immunity and subclinical measles infections in England. *Vaccine*, *22*(29), 4110-4116.

[5] Ueda, K. (2016). Epidemiology of rubella and congenital rubella syndrome in Japan before 1989. *Vaccine*, *34*(16), 1971-1974.

[6] Isaacs, D., & Menser, M. (1990). Measles, mumps, rubella, and varicella. *The Lancet*, *335*(8702), 1384-1387.

[7] Abrams, S., Beutels, P., & Hens, N. (2014). Assessing mumps outbreak risk in highly vaccinated populations using spatial seroprevalence data. *American journal of epidemiology*, kwu014.

[8] Park, S. H. (2015). Resurgence of mumps in Korea. *Infection & chemotherapy*, *47*(1), 1-11.

[9] Snijders, B. E., van Lier, A., van de Kassteele, J., Fanoy, E. B., Ruijs, W. L., Hulshof, F., ... & de Melker, H. E. (2012). Mumps vaccine effectiveness in primary schools and households, the Netherlands, 2008. *Vaccine*, *30*(19), 2999-3002.

[10] Dayan, G. H., Quinlisk, M. P., Parker, A. A., Barskey, A. E., Harris, M. L., Schwartz, J. M. H., ... & Clayton, J. (2008). Recent resurgence of mumps in the United States. *New England Journal of Medicine*, *358*(15), 1580-1589.

[11] Anderson, R. M., May, R. M., & Anderson, B. (1992). *Infectious diseases of humans: dynamics and control* (Vol. 28). Oxford: Oxford university press.

[12] Nardone, A., Pebody, R. G., van Den Hof, S., Levy-Bruhl, D., Plesner, A. M., Rota, M. C., ... & Edmunds, W. J. (2003). Sero-epidemiology of mumps in western Europe. *Epidemiology and infection*, *131*(01), 691-701.

[13] van Boven, M., Ruijs, W. L., Wallinga, J., O'Neill, P. D., & Hahne, S. (2013). Estimation of vaccine efficacy and critical vaccination coverage in partially observed outbreaks. *PLoS Comput Biol*, *9*(5), e1003061.

[14] Donaghy, M., Cameron, J. C., & Friederichs, V. (2006). Increasing incidence of mumps in Scotland: options for reducing transmission. *Journal of clinical virology*, *35*(2), 121-129.

[15] DeStefano, F., Price, C. S., & Weintraub, E. S. (2013). Increasing exposure to antibody-stimulating proteins and polysaccharides in vaccines is not associated with risk of autism. *The Journal of pediatrics*, *163*(2), 561-567.

[16] Hethcote, H. W. (2000). The mathematics of infectious diseases. *SIAM review*, *42*(4), 599-653.

[17] Brisson, M., Melkonyan, G., Drolet, M., De Serres, G., Thibeault, R., & De Wals, P. (2010). Modeling the impact of one-and two-dose varicella vaccination on the epidemiology of varicella and zoster. *Vaccine*, *28*(19), 3385-3397.

[18] Ferguson, N. M., Nokes, D. J., & Anderson, R. M. (1996). Dynamical complexity in age-structured models of the transmission of the measles virus: epidemiological implications at high levels of vaccine uptake. *Mathematical biosciences*, *138*(2), 101-130.

[19] Andreasen, V. (1993). The effect of age-dependent host mortality on the dynamics of an endemic disease. *Mathematical biosciences*, *114*(1), 29-58.

[20] Snijders, B. E., van Lier, A., van de Kassteele, J., Fanoy, E. B., Ruijs, W. L., Hulshof, F., ... & de Melker, H. E. (2012). Mumps vaccine effectiveness in primary schools and households, the Netherlands, 2008. *Vaccine*, *30*(19), 2999-3002.

[21] Centers for Disease Control and Prevention (CDC. (2009). Mumps outbreak-New York, New Jersey, Quebec, 2009. *MMWR. Morbidity and mortality weekly report*, *58*(45), 1270.

[22] Heffernan, J. M., & Keeling, M. J. (2009). Implications of vaccination and waning immunity. *Proceedings of the Royal Society of London B: Biological Sciences*, rspb-2009.

[23] LeBaron, C. W., Forghani, B., Beck, C., Brown, C., Bi, D., Cossen, C., & Sullivan, B. J. (2009). Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine. *Journal of Infectious Diseases*, *199*(4), 552-560.

[24] Ross L. Cameron and A. Smith-Palmer, (2015). Measles, mumps, rubella and whooping cough illness, routine childhood vaccine uptake. Immunisation Team, HPS weekly report, 49: 251-259.

[25] Keeling, M. J., & Grenfell, B. T. (2002). Understanding the persistence of measles: reconciling theory, simulation and observation. *Proceedings of the Royal Society of London B: Biological Sciences*, *269*(1489), 335-343.

[26]Anderson, R. M., Grenfell, B. T., & May, R. M. (1984). Oscillatory fluctuations in the incidence of infectious disease and the impact of vaccination: time series analysis. *Journal of Hygiene*, *93*(03), 587-608.

[27] Anderson, R. M., Crombie, J. A., & Grenfell, B. T. (1987). The epidemiology of mumps in the UK: a preliminary study of virus transmission, herd immunity and the potential impact of immunization. *Epidemiology and infection*, *99*(01), 65-84.

[28] Department of Health Protection Scotland, National surveillance center.

[29] Edmunds, W. J., Gay, N. J., Kretzschmar, M., Pebody, R. G., & Wachmann, H. (2000). The pre-vaccination epidemiology of measles, mumps and rubella in Europe: implications for modelling studies. *Epidemiology and infection*, *125*(03), 635-650.

[30] Ciocchetta, F., & Hillston, J. (2009). Bio-PEPA: A framework for the modelling and analysis of biological systems. *Theoretical Computer Science*, *410*(33-34), 3065-3084.

[31] Benkirane, S., Norman, R., Scott, E., & Shankland, C. (2012, August). Measles epidemics and PEPA: an exploration of historic disease dynamics using process algebra. In *International Symposium on Formal Methods* (pp. 101-115). Springer Berlin Heidelberg.

[32] Hamami D, Atmani B., (2013). Tuberculosis Modelling Using Bio-PEPA Approach. International Journal of Medical, Health, Biomedical, Bioengineering and Pharmaceutical Engineering, 7: 183-190.

[33] Greenhalgh, D., & Sfikas, N. (2003). Vaccination programs against mumps in the United Kingdom. *Journal of Medical Informatics & Technologies*, *5*.

[34] Glass K, Grenfell BT (2003) Antibody dynamics in childhood diseases: waning and boosting of immunity and the impact of vaccination. J. Theor. Biol. 221(1):121–131.

[35] Barbarossa MV, Röst G (2015) Immuno-epidemiology of a population structured by immune status: a mathematical study of waning immunity and immune system boosting. J. Math. Biol., 71(6):1737–1770.

[36] Fanoy, E. B., Cremer, J., Ferreira, J. A., Dittrich, S., van Lier, A., Hahné, S. J., ... & van Binnendijk, R. S. (2011). Transmission of mumps virus from mumps-vaccinated individuals to close contacts. *Vaccine*, *29*(51), 9551-9556.

[37] Brockhoff, H. J., Mollema, L., Sonder, G. J., Postema, C. A., van Binnendijk, R. S., Kohl, R. H., ... & Hahné, S. J. (2010). Mumps outbreak in a highly vaccinated student population, The Netherlands, 2004. *Vaccine*, *28*(17), 2932-2936.

[38] Centers for Disease Control and Prevention (CDC. (2009). Mumps outbreak-New York, New Jersey, Quebec, 2009. *MMWR. Morbidity and mortality weekly report*, *58*(45), 1270.

[39] Keeling, M. J., & Rohani, P. (2008). *Modeling infectious diseases in humans and animals*. Princeton University Press.

[40] Finkenstädt, B., Keeling, M., & Grenfell, B. (1998). Patterns of density dependence in measles dynamics. *Proceedings of the Royal Society of London B: Biological Sciences*, *265*(1398), 753-762.

[41] Infromation Service Division. Childhood Immunisation Statistics, http://www.isdscotland.org/Health-Topics/Child-Health/Immunisation/

[42] Morgan-Capner, P., Wright, J., Miller, C. L., & Miller, E. (1988). Surveillance of antibody to measles, mumps, and rubella by age. *BMJ*, *297*(6651), 770-772.

[43] England PH: Mumps: the green book, chapter 23. Mumps immunisation information for public health professionals. In: Immunisation against infectious disease Mumps: guidance, data and analysis 2013.

[44] R. Cameron. Health Protection Scotland, immunization team. Personal communication. Jan. 21, 2016.

[45] Scherer, A., & McLean, A. (2002). Mathematical models of vaccination. *British Medical Bulletin*, *62*(1), 187-199.

[46] Galazka, A. M., Robertson, S. E., & Kraigher, A. (1999). Mumps and mumps vaccine: a global review. *Bulletin of the World Health Organization*, *77*(1), 3.

[47] Takla, A., Wichmann, O., Klinc, C., Hautmann, H., Rieck, T., & Koch, J. (2013). Mumps epidemiology in Germany 2007-11. Euro Surveill, 18(33):20557.

[48] Minitab 17 Statistical Software (2010). [Computer software]. State College, PA: Minitab, Inc. (www.minitab.com)

[49] Cordeiro, E., Ferreira, M., Rodrigues, F., Palminha, P., Vinagre, E., & Pimentel, J. P. (2015). Mumps Outbreak among Highly Vaccinated Teenagers and Children in the Central Region of Portugal, 2012-2013. *Acta medica portuguesa*, *28*(4), 435-441.

[50] Gouma, S., Hahné, S. J., Gijselaar, D. B., Koopmans, M. P., & van Binnendijk, R. S. (2016). Severity of mumps disease is related to MMR vaccination status and viral shedding. *Vaccine*, *34*(16), 1868-1873.

[51] Roy, M., Son, A., & May, R. M. (1982). Directly transmitted infectious diseases: control by vaccination. *Science*, *215*, 26.

[52] Gay, N. J. (1998). Modeling measles, mumps, and rubella: implications for the design of vaccination programs. *Infection Control & Hospital Epidemiology*, *19*(08), 570-573.

[53] Marco, D., Scott, E., Cairns, D., Graham, A., Allen, J., Mahajan, S., & Shankland, C. (2012). Investigating co-infection dynamics through evolution of Bio-PEPA model parameters: a combined process algebra and evolutionary computing approach. In *Computational Methods in Systems Biology* (pp. 227-246). Springer Berlin Heidelberg.

[54] Galbraith, N. S., Pusey, J., Young, S. J., Crombie, D. L., & Sparks, J. P. (1984). Mumps surveillance in England and Wales 1962-81. *The Lancet*, *323*(8368), 91-94.

[55] Savage, E., Ramsay, M., & Crowcroft, N. (2004). Increases in mumps cases in England and Wales in 2004. *Eurosurveillance Weekly*, *8*, 3-4.http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=2591

## 10 Appendix 1: Bio-PEPA Model

A Bio-PEPA model, illustrated below, is defined by three main components: species, functions of species dynamics and rates at which those species evolve. Modelling mumps in Bio-PEPA requires describing fully those features accordingly to the model in Fig. 2 and its description above.

*Rates*. All rates fully described in Table 1 are reported in Bio-PEPA code, from line 1to 12. In addition, Bio-PEPA defines the parameter "location" (from line 13 and line 18). As in our model, the population is considered homogeneous, therefore all individuals belong to the same space. Seasonality is expressed by using the Heaviside function (H). As noted by Marco et al. [53]: " Heaviside function (H) is used to switch customised behaviours on or off in the kinetic laws, this gives a binary valued function from time". The lines from 19 to 22 code two seasons. The system moves instantaneously from the high epidemic season defined from October to May to the low epidemic season defined from June to September.

*Species and Functional rates (KineticLawOf).* According to the compartments shown in Fig. 2, seven species are defined: S1, S2, V1, V2, E, I, R. Species carry out actions (**kinetic laws)** leading to increase/decrease their level (from line 24 to 40). Actions occur at a rate determined by the kinetic law. Most of these kinetic laws are simple mass action terms defined by the parameters described in the Table 1. Since species interact, the dynamics of each species may affect the level of other species. The scale of this dynamic is bounded by the functional rate specified for each species. For example the action described in line 34, related to incubation and used both by species "E" and "I", leads to a decrease in the Exposed species (line 43) expressed by the operator "<<", while it leads Infected species to increase using the operator ">>". Bio-PEPA species can carry out different activities at each time step, by using the operator '+'.

The last line of the model (line 48) defines the interaction between species, and their initial sizes.

**Parameters**

```
1 D_R = 0.000037;
2 Beta1 =0.80;
3 Beta2 =1.03;
4 Beta = 0.45;
5 Mu2= 0.0000028;
6 Mu3= 0.000025;
7 Mu1 = 0.0000021;
8 Alpha = 0.05;
9 Gama  = 0.167;
10 imrate1 =0.07;
11 Tau= 0.00034;
12 Delta=Tau/2;
13 sizeOutside = 110000;
14 sizeLocal = 5300000;
15 location world : size =5200000 , type = compartment;
16 location Local in world: size = sizeLocal, type = compartment;
17 location Local in world: size = sizeLocal, type = compartment;
18 location Outside in world : size = sizeOutside, type = compartment;
19 thigh = 4;
20 tlow = 9;
21 month = floor(time/30);
22 season_time = 1-H( ((month - 12*floor(month/12)) - tlow)*(thigh-(month - 12*floor(month/12))) );
23 N = (S1@Local +E@Local + I@Local + R@Local +S2@Local   + MMR1@Local + MMR2@Local);
```

**Kinetic Laws**

```
24 kineticLawOf BIRTH1:  Mu1 * N;
25 kineticLawOf BIRTH2:  Mu2 * N;
26 kineticLawOf BIRTH3:  Mu3 * N;
27 kineticLawOf  MMR1_S2: MMR1@Local *Tau;
28 kineticLawOf  MMR2_S2: MMR2@Local *Delta;
29 kineticLawOf Death_MMR1 : D_R * MMR1@Local;
30 kineticLawOf Death_MMR2 : D_R * MMR2@Local;
31 kineticLawOf immigration : imrate1/10000;
32 kineticLawOf S1_E: (Beta1 * S1@Local * I@Local)/N * (season_time)
                        + (1-season_time)*(Beta * S1@Local * I@Local)/N ;
33 kineticLawOf S2_E: (Beta2 * S2@Local * I@Local)/N * (season_time)
                       + (1-season_time)* (Beta * S2@Local * I@Local)/N;
34 kineticLawOf E_I: Alpha * E@Local;
35 kineticLawOf I_R: Gama * I@Local;
36 kineticLawOf Death_S1: D_R * S1@Local;
37 kineticLawOf Death_I: D_R * I@Local ;
38 kineticLawOf Death_E: D_R * E@Local;
39 kineticLawOf Death_S2: D_R * S2@Local;
40 kineticLawOf Death_R: D_R * R@Local;
```

**Species**

```
41 S1 = (BIRTH1,1) >>  S1@Local  + (S1_E,1) << S1@Local + Death_S1 << S1@Local;
42 S2 = (S2_E,1) << S2@Local + Death_S2 << S2@Local + (MMR2_S2,1) >> S2@Local +(MMR1_S2,1) >>
          S2@Local;
43 E = (S1_E,1) >> E@Local +(S2_E,1) >> E@Local +(E_I,1) << E@Local+  Death_E << E@Local;
44 I = (E_I,1) >> I@Local +(I_R,1) << I@Local +   Death_I << I@Local + immigration[Outside -> Local](.)I
     + (S1_E,1) (.) I+ (S2_E,1) (.) I;
45 R = (I_R,1) >> R@Local+ Death_R << R@Local ;
46 MMR1 = (BIRTH2,1) >> MMR1@Local  + (MMR1_S2,1) << MMR1@Local+ Death_MMR1 << ;
47 MMR2 = (BIRTH3,1)>> MMR2@Local + (MMR2_S2,1) << MMR2@Local + Death_MMR2 <<  ;
```

**Model component**

```
48 S1@Local[1100000]<*> S2@Local[305500]<*>  E@Local[0]<*> I@Local[20]<*> R@Local[3018600]<*>
  MMR1@Local[29250] <*>MMR2@Local[276250] <*> I@Outside[100000]
```

# 11 Appendix 2: Sensitivity analysis

1: Incubation period experiments

The analysis per ANOVA is carried out for 14 experiments where the incubation period varied from 12 to 25 days per one step day. The results indicate that at 95% of confidence, no significant statistical differences between experiments ($p = 0.968$) and then the null hypothesis (the means of experiments are equal) cannot be rejected. Hsu's MCB test and Tukey test imply that varying incubation period does not affect the number of infected; however, using simulations we can look at cycles. 100 years of simulations show that by increasing the incubation period the periodicity changes from 8 to 11 cycles.

Analysis 2: Infectious period experiments

Varying the infectious period from 6 to 9 days per one step day, indicates no significant statistical differences ( $p= 0.114$). However, the results validated by the Tukey test are in contrast with the Hsu's MCB test results. While the former shows no significant differences, the latter shows significant differences between an infectious period of 6 days ($1^{st}$ experiment) and the one of 9 days ($4^{th}$ experiment). In fact, the analysis shows clearly that the mean of the $4^{th}$ experiment (2739) is higher than the others (1808, 2113, 2276). In addition the simulation results show that increasing the infectious period increases the amplitude of the epidemic where the main gap is depicted at the first peak.

Analysis 3: Transmission rates experiments

Transmission rate experiments are based on changing the basic reproductive number $R_0$ from 4 to 11. This equates to varying the high transmission rate from 0.44 to 1.83 and the low transmission rate from 0.19 to 0.81. ANOVA analysis shows that experiments are not statistically significantly different ($p = 0.36$). However, simulations over 100 years indicate that increasing the basic reproductive number leads to a decrease in periodicity. As $R_0$ varies from 4 to 11 the period of cycles per 100 years of simulation varies from 14 to 6 and the number of cycles varies from 7 to 16 cycles. During simulations, it was observed that the first epidemic tends to occur sooner with increasing amplitude as $R_0$ increases.

Analysis 4: Immunity duration experiments

The analysis per ANOVA of the different values of immunity duration varying from 10 to 80 years, reveals statistically significant differences. In particular, the analysis depicts four different groups. The first group includes only one experiment (immunity duration = 10 years). The second group includes two experiments (immunity duration = 20 and 30). The third group includes three experiments (30, 40 and 50). The fourth group includes five experiments (40, 50, 60, 70 and 80), where the $2^{nd}$ group overlaps the third group with one experiment (30) and the third group overlaps the fourth group with two experiments (40, 50). In ANOVA, the experiment which does not share any group is considered significantly different. This implies that experiment one (10) is significantly different from all others. This is because small immunity duration tends to increase the pool of susceptibles faster and the epidemics occur sooner with higher amplitude. Moreover, this analysis supports the idea that immunity duration has a major effect on the epidemic dynamics, while varying incubation period, infectious period and transmission rates do not show such large impact on epidemic curves.

644 Analysis 4: Vaccination coverage experiments

645 Varying vaccination coverage from 75% to 95% in steps of 5 percentage points, indicates at 95% of
646 confidence no significant statistical differences (p= 0.648) between experiment and H0. The results
647 validated by Tukey test are similar to those with Hsu's MCB test results which imply that varying
648 vaccination coverage does not affect the number of infected; this fact is confirmed by simulations
649 performed where we can look at cycles. 100 years of simulations show that by increasing the
650 vaccination coverage the periodicity does not change significantly. From 80% to 95% the simulations
651 detect 10 cycles where at 75%, the periodicity of cycles is at 9 years. These findings support the
652 conclusions of DeStefano et al [15] and Donaghy et al [14].

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

# 12 Appendix 3: Mumps data in England and Wales

**Table 1.** Model parameters

| Parameter | Description | Value (day) | Formula |
|---|---|---|---|
| B | Birth rate | $3\ 10^{-5}$ | Number of birth / Total population |
| $\mu$ | Death rate | $3.7\ 10^{-5}$ | Number of death / Total population |
| $\mu_1$ | No-vaccination rate | $2.1\ 10^{-6}$ | Birth rate -($\mu_2$+$\mu_3$) |
| $\mu_2$ | Vaccination rate (MMR1) | $2.8\ 10^{-6}$ | Birth rate * VC1 |
| $\mu_3$ | Vaccination rate (MMR2) | $2.5\ 10^{-5}$ | Birth rate * VC2 |
| $\tau$ | Waning immunity rate (MMR1) | $3.4\ 10^{-4}$ | 1/immunity duration of MMR1 |
| $\delta$ | Waning immunity rate (MMR2) | $\tau/2$ | 1/immunity duration of MMR2 |
| | Transmission rate for : | | |
| $\beta 1$ | - high season and native susceptible | 0.7 | |
| $\beta 2$ | - high season and modified susceptible | 0.9 | $\beta = R_0 * \gamma$ |
| $\beta 3$ | - low season | 0.4 | |
| T[3] | Inter-epidemic period | [2-5] | $T = 2\pi * \sqrt{A(\frac{1}{\alpha}+\frac{1}{\gamma})}$ [42] where A: mean age of infection |
| $1/\alpha$ | Incubation period | [12-25] | 1/infection rate |
| $1/\gamma$ | Infectious period | [7-9] | 1/recovery rate |
| **$\lambda$** | **Immigration rate** | **0.07** | **Immigration $*\sqrt{\text{population}}$** |

[3] Inter-epidemic period related to a pre-vaccine era

678 **Table 2.** Sensitivity analysis summary

| **Incubation period** | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Values | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| Amplitude | 2357 | 2316 | 2229 | 2123 | 2020 | 2309 | 2280 | 2153 | 2149 | 2132 | 2020 | 1968 | 1909 | 1927 |
| Period of Cycles | 8 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 11 | 10 | 11 | 11 |

| **Infectious period** | | | | |
|---|---|---|---|---|
| Values | 6 | 7 | 8 | 9 |
| Amplitude | 1808 | 2132 | 2276 | 2739 |
| Period of Cycles | 10 | 10 | 11 | 10 |

| **Basic reproductive number** | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| Values | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| Amplitude | 1690 | 1708 | 2132 | 2134 | 2256 | 2320 | 2289 | 2407 |
| Period of Cycles | 14 | 12 | 10 | 9 | 9 | 8 | 7 | 6 |

| **Immunity duration** | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| Values | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 |
| Amplitude | 1873 | 1245 | 909 | 668 | 555 | 440 | 371 | 306 |
| Period of Cycles | 10 | 8 | 7 | 7 | 6 | 5 | 5 | 4.5 |

| **Vaccination coverage** | | | | | |
|---|---|---|---|---|---|
| Values | 75 | 80 | 85 | 90 | 95 |
| Amplitude (100 years peaks) | 1694 | 1660 | 1552 | 1536 | 1413 |
| Amplitude (10 first peaks) | 1602 | 1587 | 1547 | 1504 | 1410 |
| Period of Cycles | 9 | 10 | 10 | 10 | 10 |

**Fig. 1** Confirmed mumps cases, Scotland 1988-2016 and MMR vaccine coverage

**Fig. 2** Mumps structure

**Fig. 3** Predicted incidence of mumps from 2004 to 2016: : (a) Scenario 1- No vaccination, (b) Scenario 2- Vaccination without waning immunity, (c) Scenario 3- Vaccination with waning immunity, (d) ) Predicted-Observed data for mumps from 1996 to 2016..

**Fig. 4** Inter-epidemic period against basic reproductive rate R0 for pre-vaccine era

**Fig. 5** Infected against vaccination coverage

**Fig. 6** The effect of waning immunity: Left axis: Infected-unvaccinated, Infected-unvaccinated/vaccinated. Right axix: natively susceptible and modified susceptible.

**Fig. 7** Infected against duration of immunity

**Fig. 8** Inter-epidemic period against basic reproductive rate R0 for post-vaccine era

**Fig. 9** Confirmed mumps cases, England and Wales and MMR vaccine coverage

Figure 01.JPEG



Figure 02.JPEG





Figure 03.JPEG



Figure 04.JPEG



Figure 05.JPEG



Figure 06.JPEG



Figure 07.JPEG



Figure 08.JPEG



Figure 09.JPEG




(a) data from 1967 to 2014 excluding (1982-1995) [37]




(b) data from 1984 to 2004 taken from [38]